Brokers Offer Predictions for Hims & Hers Health, Inc.’s FY2026 Earnings (NYSE:HIMS)
Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) – Stock analysts at Leerink Partnrs issued their FY2026 earnings per share (EPS) estimates for shares of Hims & Hers Health in a research report issued on Monday, February 26th. Leerink Partnrs analyst M. Cherny forecasts that the company will post earnings of $0.23 per share for the year. Leerink Partnrs currently has a “Market Perform” rating on the stock. The consensus estimate for Hims & Hers Health’s current full-year earnings is ($0.14) per share.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative return on equity of 11.22% and a negative net margin of 4.50%. The business had revenue of $246.60 million during the quarter, compared to analysts’ expectations of $245.84 million. During the same period in the previous year, the business earned ($0.05) earnings per share. The business’s revenue was up 47.4% compared to the same quarter last year.
HIMS has been the subject of several other research reports. Citigroup upped their price target on shares of Hims & Hers Health from $12.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday. Guggenheim raised their target price on Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday. SVB Leerink assumed coverage on Hims & Hers Health in a research report on Monday. They set a “market perform” rating and a $10.00 price target for the company. Truist Financial raised their price objective on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a report on Tuesday. Finally, Imperial Capital initiated coverage on shares of Hims & Hers Health in a report on Thursday, December 7th. They set an “inline” rating and a $9.00 target price for the company. Five investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.50.
View Our Latest Research Report on Hims & Hers Health
Hims & Hers Health Stock Performance
NYSE:HIMS opened at $13.42 on Tuesday. The stock has a market capitalization of $2.84 billion, a PE ratio of -78.94 and a beta of 0.77. Hims & Hers Health has a fifty-two week low of $5.65 and a fifty-two week high of $13.91. The company has a fifty day moving average of $9.13 and a two-hundred day moving average of $7.75.
Institutional Trading of Hims & Hers Health
Hedge funds have recently made changes to their positions in the business. Belpointe Asset Management LLC lifted its holdings in Hims & Hers Health by 10.0% during the 4th quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock worth $118,000 after buying an additional 1,205 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Hims & Hers Health by 9.6% in the fourth quarter. Principal Financial Group Inc. now owns 14,130 shares of the company’s stock valued at $126,000 after acquiring an additional 1,234 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of Hims & Hers Health by 1.1% in the second quarter. Russell Investments Group Ltd. now owns 128,290 shares of the company’s stock valued at $1,206,000 after acquiring an additional 1,399 shares in the last quarter. Osaic Holdings Inc. raised its stake in shares of Hims & Hers Health by 29.1% in the second quarter. Osaic Holdings Inc. now owns 6,213 shares of the company’s stock valued at $58,000 after acquiring an additional 1,400 shares in the last quarter. Finally, Virtu Financial LLC raised its stake in shares of Hims & Hers Health by 8.4% in the fourth quarter. Virtu Financial LLC now owns 18,441 shares of the company’s stock valued at $118,000 after acquiring an additional 1,430 shares in the last quarter. Institutional investors and hedge funds own 61.45% of the company’s stock.
Insider Buying and Selling at Hims & Hers Health
In other news, CEO Andrew Dudum sold 97,208 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $9.58, for a total transaction of $931,252.64. Following the completion of the transaction, the chief executive officer now directly owns 51,653 shares in the company, valued at approximately $494,835.74. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider Soleil Boughton sold 22,839 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $10.03, for a total transaction of $229,075.17. Following the transaction, the insider now owns 154,345 shares of the company’s stock, valued at approximately $1,548,080.35. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 97,208 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $9.58, for a total value of $931,252.64. Following the transaction, the chief executive officer now owns 51,653 shares of the company’s stock, valued at $494,835.74. The disclosure for this sale can be found here. Insiders have sold 419,655 shares of company stock worth $3,901,881 over the last quarter. 31.63% of the stock is currently owned by company insiders.
About Hims & Hers Health
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.
Featured Articles
Receive News & Ratings for Hims & Hers Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hims & Hers Health and related companies with MarketBeat.com’s FREE daily email newsletter.
